FRED X血流导向支架治疗颅内动脉瘤:系统评价与Meta分析
该系统评价与Meta分析纳入8项研究、480例患者、531个动脉瘤,评估FRED X血流导向支架治疗颅内动脉瘤的安全性和有效性。末次随访时充分闭塞率为85.9%(95%CI=79%-91.8%),症状性并发症发生率为4%(95%CI=0.7%-9%),总死亡率为0.34%(95%CI=0.0%-1.7%),支架内狭窄发生率为1.2%。作者结论认为FRED-X安全有效,但需长期研究确认其耐久性和更广泛应用潜力。
要点
- 末次随访动脉瘤充分闭塞率为85.9%(95%CI=79%-91.8%)。
- 症状性并发症发生率为4%(95%CI=0.7%-9%),总死亡率为0.34%(95%CI=0.0%-1.7%)。
- 支架内狭窄发生率为1.2%,平均手术时间68.2分钟(SD=38.1),透视时间23.5分钟(SD=11.7)。
核心结论
- FRED-X血流导向支架治疗颅内动脉瘤安全有效,并发症率低、支架内狭窄少、手术指标高效,但需长期研究确认其耐久性和更广泛应用潜力。
研究设计与样本
- 系统评价与Meta分析,检索PubMed/MEDLINE、Embase、Google Scholar和Web of Science四个数据库,纳入8项研究共480例患者、531个动脉瘤,采用逆方差法合并比例,二分类结局用OR和95%CI分析,主要结局为末次随访动脉瘤闭塞。
诊断标准与关键数值
- 末次随访动脉瘤充分闭塞率为85.9%(95%CI=79%-91.8%)。
- 症状性并发症发生率为4%(95%CI=0.7%-9%)。
- 总死亡率为0.34%(95%CI=0.0%-1.7%)。
- 支架内狭窄发生率为1.2%。
- 未破裂动脉瘤占84.1%(95%CI=66%-96.5%),前循环动脉瘤占86.7%(95%CI=75.9%-94.8%),主要位于颈内动脉(64.2%)。
临床应用与阅片要点
- 患者平均年龄56.2岁,女性占81.5%,平均动脉瘤大小6.4 mm(SD=5.1)。
- 平均手术时间68.2分钟(SD=38.1),平均透视时间23.5分钟(SD=11.7)。
局限性
- 作者指出需长期研究确认FRED-X的耐久性和更广泛应用潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: The Flow Re-Direction Endoluminal Device X (FREDTM-X, MicroVention, Inc., Terumo Corporation, USA), introduces a dual-layer structure and antithrombotic surface technology, designed to address the limitations of earlier devices in reducing material thrombogenicity and promoting better vessel endothelialization for brain aneurysm. Herein, we present the first systematic review and meta-analysis summarizing available literature to reach a consensus regarding the safety and effectiveness of FREDTM-X.
METHODS: A literature search was performed in four electronic databases, PubMed/MEDLINE, Embase, Google Scholar, and Web of Science, for studies that evaluated FRED-X in managing intracranial aneurysms. Proportions were pooled employing the inverse variance method, and binary outcomes were analyzed using odds ratio (OR) and 95% confidence interval (CI). The primary outcome was an aneurysm occlusion at the final follow-up.
RESULTS: Eight studies involving 480 patients and 531 aneurysms were included. Most patients were female (81.5%), with a mean age of 56.2 years. Most aneurysms were unruptured (84.1%, 95%CI = 66% - 96.5%) and located in the anterior circulation (86.7%, 95%CI = 75.9% - 94.8%), primarily in the internal carotid artery (64.2%). Procedural data showed a mean procedure time of 68.2 (SD = 38.1) minutes and a fluoroscopy time of 23.5 (SD = 11.7) minutes. The mean aneurysm size was 6.4 mm (SD = 5.1). In-stent stenosis occurred in 1.2% of cases. Adequate occlusion was achieved in 85.9% (95%CI = 79% - 91.8%) of patients at the last follow-up. Symptomatic complications occurred in 4% (95%CI = 0.7% - 9%) of patients, and the overall mortality rate was 0.34% (95%CI = 0.0% - 1.7%).
CONCLUSION: The FRED-X flow diverter is safe and effective in treating intracranial aneurysms. It has low complication rates, minimal in-stent stenosis, and efficient procedural metrics. Long-term studies must confirm its durability and potential for broader applications.
引用
- Mortezaei A, Essibayi MA, Ghorbi L, et al. FRED X flow diversion stent for intracranial aneurysms: a systematic review and meta-analysis. Neuroradiology. 2025. PMID: 40970960. doi:10.1007/s00234-025-03755-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。